Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma
Authors: David Roife
Michael Pratt
Mayrim V Rios Perez
Xinqun Li
Frederick F Lang
Rolf A Brekken
Juan Fueyo-Margareto
Ya&#x27;an Kang
Joy Gumin
Jason B Fleming
Bingbing Dai
Journal: Molecular Cancer Therapeutics (2017)
Discipline: CLINICAL MEDICINE
Keywords: Delta-24-RGD; oncolytic virus; p16/RB/E2F pathway; pancreatic ductal adenocarcinoma (PDAC); cyclin D1
Affiliations: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, Texas., Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. .

Abstract:  Delta-24-RGD (DNX-2401) is a conditional replication-competent oncolytic virus engineered to preferentially replicate in and lyse tumor cells with abnormality of p16/RB/E2F pathway. In a phase I clinical trial, Delta-24-RGD has shown favorable safety profile and promising clinical efficacy in brain tumor, which prompted us to evaluate its anticancer activity in pancreatic ductal adenocarcinoma (PDAC), which also has high frequency of homozygous deletion and promoter methylation of CDKN2A encoding the p16 protein. Our results demonstrate that Delta-24-RGD can induce dramatic cytotoxicity in a subset of PDAC cell lines with high cyclin D1 expression. Induction of autophagy and apoptosis by Delta-24-RGD in sensitive PDAC cells was confirmed with LC3B-GFP autophagy reporter and acridine orange staining as well as Western blotting analysis of LC3B-II expression. Notably, we found that Delta-24-RGD induced phosphatidylserine exposure in infected cells independent of cells' sensitivity to Delta-24-RGD, which renders a rationale for combination of Delta-24-RGD viral therapy and phosphatidylserine targeting antibody for PDAC. In a mouse PDAC model derived from a liver metastatic pancreatic cancer cell line, Delta-24-RGD significantly inhibited tumor growth compared with control (P &lt; 0.001), and combination of phosphatidylserine targeting antibody 1N11 further enhanced its anticancer activity (P &lt; 0.01) possibly through inducing synergistic anticancer immune responses. Given that these 2 agents are currently in clinical evaluation, our study warrants further clinical evaluation of this novel combination strategy in pancreatic cancer therapy. Mol Cancer Ther; 16(4); 662-70. ©2016 AACR. 

Retracted: No

PubPeer comments:
 Two images in Figure 6 appear to overlap, but are differently described. Shown below with enhanced contrast. *** ![file] , 
 This paper appears to include an image which also appeared in another paper where seems to be described differently by the authors. Could the authors determine for readers in which paper the image was labeled correctly? Cell Death Disease (2021), doi: 10.1038 s41419-021-03970-8, https: pubpeer.com publications E03988A29650D708D6D41A7633BFC0 Molecular Cancer Therapeutics (2017), doi: 10.1158 1535-7163.mct-16-0526, https: pubpeer.com publications 3B71C6415F73E5BBC43785EFD3BE4D *** ![file] ,